Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,553 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT06459791Recruiting
Personalized treatment for advanced breast cancer using lab-grown tumor models
This trial tests a personalized approach to cancer treatment. Doctors will grow a ‘mini-tumor’ from a biopsy of your cancer in the lab to help find the best therapy for you. It is for people with advanced breast cancer that has not responded well to standard treatments.
ParisAges 18 years+ - NCT05578053Recruiting
Dalpiciclib for hormone receptor–positive advanced breast cancer
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Shijiazhuang, HebeiAges 18 years+ - NCT04254263RecruitingPhase 3
Pyrotinib after breast cancer therapy for HER2-positive early disease
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04159142RecruitingPhase 2
Testing two chemo combos for advanced triple-negative breast cancer
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
Shijiazhuang, HebeiAges 18–70 - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
Sacramento, CaliforniaAges 18 years+ - NCT06453486RecruitingPhase 2
High dose radiation for pancreatic cancer after chemo
This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.
Toronto, OntarioAges 18 years+ - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT06435286RecruitingPhase 2
Testing a new imaging tool for esophageal cancer screening
This study tests a new imaging technology (optical biopsy) that may help doctors find early signs of esophageal cancer during a routine endoscopy. It is for people who are already scheduled for a screening procedure with a special dye (Lugol's chromoendoscopy).
Houston, TexasAges 18 years+ - NCT06439485RecruitingPhase 1/Phase 2
Combination drug therapy for advanced bile duct cancer with FGFR2 change
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06417801Recruiting
Study of ESR1 gene changes in blood in advanced breast cancer
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
Salvador, Estado de BahiaAges 18–100 - NCT06401603RecruitingPhase 1
Study of three drugs for advanced CML and Ph+ AML
This trial tests a combination of three drugs (decitabine, lisaftoclax, and olverembatinib) for people with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia who have not responded to or could not tolerate previous treatments.
Houston, TexasAges 18 years+ - NCT06380101Recruiting
Special diet with standard therapy for rectal cancer
This trial tests a special medical food that limits certain amino acids (building blocks of protein) during standard treatment for rectal cancer. The goal is to see if this diet helps the treatment work better while reducing side effects.
Tampa, FloridaAges 18–100 - NCT06364371Recruiting
Predicting rectal cancer treatment response using multi-omics
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
Guangzhou, GuangdongAges 18–80 - NCT06368141RecruitingPhase 2
Chemo plus immunotherapy before surgery for colon cancer
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06253611RecruitingPhase 2
Probiotic plus immunotherapy and chemo for stomach cancer
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
AngersAges 18 years+ - NCT06349408RecruitingPhase 1
Testing IBI3001 for advanced solid tumors
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06350318RecruitingPhase 2
Rituximab and Zanubrutinib for slow-growing B-cell lymphomas
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
Tampa, FloridaAges 18 years+ - NCT06349148Recruiting
Nutrition therapy for advanced cervical cancer
This study tests whether a special nutrition plan (immunonutrition) helps people with advanced cervical cancer who are having chemoradiation. It is for those who are also malnourished.
BeijingAges 18 years+ - NCT06329869RecruitingPhase 2
A study of sacituzumab govitecan for advanced esophageal cancer
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
TaipeiAges 18 years+ - NCT06312982RecruitingPhase 2/Phase 3
Chemo, radiation, and immunotherapy before rectal cancer surgery
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06302621RecruitingPhase 1
Pemigatinib plus afatinib for advanced solid tumors with FGFR changes
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Boston, MassachusettsAges 18 years+ - NCT06298734Recruiting
Exercise and diet study for melanoma patients on immunotherapy
This study tests whether adding high-intensity exercise and a high-fiber diet can improve how well immunotherapy works for people with melanoma. It might help you if you are already on immunotherapy and are not currently very active or eating a lot of fiber.
Boston, MassachusettsAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Duarte, CaliforniaAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,553 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.